Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
We send one confirmation email first. Only emails about AARD, unsubscribe in one click. Privacy
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
| Drug | Indication | Most advanced trial | Status |
|---|---|---|---|
| ARD-101 | Hyperphagia | Phase 3 · NCT07197034 | Terminated |
| High Dose ARD-501 | Autism Spectrum Disorder | Phase 2 · NCT06126653 | Completed |
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
AARD holds $73.9M in cash and short-term investments (as of Jun 30, 2026) and burns about $18.2M/quarter from operations, an estimated runway of 12.2 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure: 43 · Elevated
Recent financing filings on SEC EDGAR:
Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when AARD files for a raise →
| Holder | Type | Shares | % of shares | As of |
|---|---|---|---|---|
| Decheng Capital Global Life Sciences Fun 10% owner |
Insider | 3,917,299 | 17.90% | 2025-02-14 |
| Tien-Li Lee Chief Executive Officer, Director, 10% o · +793,951 options |
Insider | 3,025,641 | 13.83% | 2025-12-11 |
| Vickers Venture Fund VI Pte Ltd 10% owner |
Insider | 2,050,902 | 9.37% | 2025-02-14 |
| Cormorant Asset Management, LP Former 10% Owner |
Insider | 987,689 | 4.51% | 2025-02-14 |
| Jeffrey Chi Director · +105,981 options |
Insider | 133,364 | 0.61% | 2025-02-14 |
| Nelson Sun Chief Financial & Operating Officer · +280,375 options |
Insider | 35,475 | 0.16% | 2026-09-10 |
| Bryan Jones Chief Operating Officer · +162,085 options |
Insider | 1,250 | 0.01% | 2025-10-15 |
Share count 21,884,846 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for AARD and every other ticker you follow. Card required, cancel anytime.
Start 7-day free trial →